https://topoisomerasesignaling.....com/proper-aortic-p
The record, with the unique identifier 251936, is to be returned. Advanced-stage non-small cell lung cancer (aNSCLC) patients are often treated with immune checkpoint inhibitors (ICIs), which are deemed the most promising therapy available. Regrettably, a unified set of accuracy biomarkers and a systematic predictive model, explicitly designed to predict prognostic and severe immune-related adverse events (irAEs), have
Beğen
Yorum Yap
Paylaş
